Our study showed that the prevalence of harbouring BCR::ABL1 in the first-degree relatives of known CML patients was approximately 4%, higher than the 0.5% prevalence observed in the normal population. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.